131 I-omburtamab

Phase 2

Y-mAbs Therapeutics, Inc. (YMAB)

00%

What is LOA?

Phase 2

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

Upcoming Catalysts

What are catalysts?

Jul '27

YMABPhase 2$391M

131 I-omburtamab Phase 2 Est. Readout

131 I-omburtamab• Desmoplastic Small Round Cell Tumor31

Jul 2027~Confirmed

CT.gov

00%

Competitive Landscape

0 competitors in Desmoplastic Small Round Cell Tumor

View Full Landscape

Drug Information

Target Indication

Desmoplastic Small Round Cell Tumor

Clinical Trial

NCT04022213

Last updated: 8/15/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Source: FDA Orange Book

Drug Science

Mechanism of action & safety profile

Developer

YMAB

Y-mAbs Therapeutics, Inc.

Pharmaceutical Preparations•North America•NASDAQ

Related Pipeline

GM-CSF + NaxitamabPhase 2

Neuroblastoma

Hu3F8 With GM-CSFPhase 2

Neuroblastoma

adjuvant OPT-821 in a vaccine containing two antigens (GD2L and GD3L) covalently linked to KLHPhase 2

Neuroblastoma

Hu3F8Phase 2

Neuroblastoma

NaxitamabPhase 2

Neuroblastoma

View full pipeline

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts